A toll-like receptor 9 antagonist reduces pain hypersensitivity and the inflammatory response in spinal cord injury

Neurobiology of Disease

Volumn 54, Issue , 2013, Pages 194-205

  David, Brian T ^a,b   Ratnayake, Ayomi ^a,b   Amarante, Matthew A ^a,b   Reddy, Naresh Parvath ^a,b   Dong, Wei ^a,b   Sampath, Sujitha ^a,b   Heary, Robert F ^a,b   Elkabes, Stella ^a,b  

^a RWJ Barnabas Health   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Allodynia; CpG ODN; Cytokine; Innate immunity; TLR

Indexed keywords

ANALGESIC AGENT; CD11B ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CXCL1 CHEMOKINE; CYTIDINE PHOSPHATE GUANOSINE OLIGODEOXYNUCLEOTIDE 2088; INTERLEUKIN 1BETA; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CELL COUNT; CONTUSION; DRUG MECHANISM; FEMALE; HEAT SENSITIVITY; HISTOPATHOLOGY; HYPERALGESIA; IMMUNOCOMPETENT CELL; INFLAMMATION; MOUSE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPINAL CORD INJURY; SPLEEN;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD; SPINAL CORD INJURIES; TOLL-LIKE RECEPTOR 9;

EID: 84876330870     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.12.012     Document Type: Article

References (72)

1. Austin P.J., Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J. Neuroimmunol. 2010, 229:26-50.
2. Avalos A.M., Ploegh H.L. Competition by inhibitory oligonucleotides prevents binding of CpG to C-terminal TLR9. Eur. J. Immunol. 2011, 41:2820-2827.
3. Basso D.M., Fisher L.C., Anderson A.J., Jakeman L.B., McTigue D.M., Popovich P.G. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J. Neurotrauma 2006, 23:635-659.
4. Beattie M.S. Inflammation and apoptosis: linked therapeutic targets in spinal cord injury. Trends Mol. Med. 2004, 10:580-583.
5. Beattie E.C., Stellwagen D., Morishita W., Bresnahan J.C., Ha B.K., Von Zastrow M., et al. Control of synaptic strength by glial TNFalpha. Science 2002, 295:2282-2285.
6. Beck K.D., Nguyen H.X., Galvan M.D., Salazar D.L., Woodruff T.M., Anderson A.J. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 2010, 133:433-447.
7. Bettoni I., Comelli F., Rossini C., Granucci F., Giagnoni G., Peri F., et al. Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia 2008, 56:1312-1319.
8. Bookout A.L., Mangelsdorf D.J. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl. Recept. Signal. 2003, 1:e012.
9. Caso J.R., Pradillo J.M., Hurtado O., Lorenzo P., Moro M.A., Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007, 115:1599-1608.
10. Cerullo V., Seiler M.P., Mane V., Brunetti-Pierri N., Clarke C., Bertin T.K., et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol. Ther. 2007, 15:378-385.
11. Chockalingam A., Rose W.A., Hasan M., Ju C.H., Leifer C.A. Cutting edge: a TLR9 cytoplasmic tyrosine motif is selectively required for proinflammatory cytokine production. J. Immunol. 2012, 188:527-530.
12. Dalpke A.H., Schafer M.K., Frey M., Zimmermann S., Tebbe J., Weihe E., et al. Immunostimulatory CpG-DNA activates murine microglia. J. Immunol. 2002, 168:4854-4863.
13. David B.T., Steward O. Deficits in bladder function following spinal cord injury vary depending on the level of the injury. Exp. Neurol. 2010, 226:128-135.
14. DeLeo J.A., Tanga F.Y., Tawfik V.L. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 2004, 10:40-52.
15. Duramad O., Fearon K.L., Chang B., Chan J.H., Gregorio J., Coffman R.L., et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J. Immunol. 2005, 174:5193-5200.
16. Echeverry S., Shi X.Q., Haw A., Liu H., Zhang Z.W., Zhang J. Transforming growth factor-beta1 impairs neuropathic pain through pleiotropic effects. Mol. Pain 2009, 5:16.
17. El-Hage N., Podhaizer E.M., Sturgill J., Hauser K.F. Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and morphine. Immunol. Invest. 2011, 40:498-522.
18. Ferguson A.R., Christensen R.N., Gensel J.C., Miller B.A., Sun F., Beattie E.C., et al. Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane. J. Neurosci. 2008, 28:11391-11400.
19. Funderburg N., Luciano A.A., Jiang W., Rodriguez B., Sieg S.F., Lederman M.M. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 2008, 3:e1915.
20. Gabellec M.M., Griffais R., Fillion G., Haour F. Expression of interleukin 1 alpha, interleukin 1 beta and interleukin 1 receptor antagonist mRNA in mouse brain: regulation by bacterial lipopolysaccharide (LPS) treatment. Brain Res. Mol. Brain Res. 1995, 31:122-130.
21. Gwak Y.S., Kang J., Unabia G.C., Hulsebosch C.E. Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp. Neurol. 2012, 234:362-372.
22. Hausmann O.N. Post-traumatic inflammation following spinal cord injury. Spinal Cord 2003, 41:369-378.
23. Hayashi F., Means T.K., Luster A.D. Toll-like receptors stimulate human neutrophil function. Blood 2003, 102:2660-2669.
24. He S., Liang Y., Shao F., Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:20054-20059.
25. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 2004, 10:187-192.
26. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
27. Huang H., Evankovich J., Yan W., Nace G., Zhang L., Ross M., et al. Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. Hepatology 2011, 54:999-1008.
28. Hutchinson M.R., Zhang Y., Brown K., Coats B.D., Shridhar M., Sholar P.W., et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur. J. Neurosci. 2008, 28:20-29.
29. Hylden J.L., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 1980, 67:313-316.
30. Kawasaki Y., Zhang L., Cheng J.K., Ji R.R. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J. Neurosci. 2008, 28:5189-5194.
31. Kigerl K.A., Lai W., Rivest S., Hart R.P., Satoskar A.R., Popovich P.G. Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. J. Neurochem. 2007, 102:37-50.
32. Kim D., Kim M.A., Cho I.H., Kim M.S., Lee S., Jo E.K., et al. A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J. Biol. Chem. 2007, 282:14975-14983.
33. Klinman D.M., Zeuner R., Yamada H., Gursel M., Currie D., Gursel I. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann. N. Y. Acad. Sci. 2003, 1002:112-123.
34. Knuefermann P., Baumgarten G., Koch A., Schwederski M., Velten M., Ehrentraut H., et al. CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo. Respir. Res. 2007, 8:72.
35. Krysko D.V., Agostinis P., Krysko O., Garg A.D., Bachert C., Lambrecht B.N., et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 2011, 32:157-164.
36. Lee Y.B., Yune T.Y., Baik S.Y., Shin Y.H., Du S., Rhim H., et al. Role of tumor necrosis factor-alpha in neuronal and glial apoptosis after spinal cord injury. Exp. Neurol. 2000, 166:190-195.
37. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58:253-263.
38. Lehnardt S., Lehmann S., Kaul D., Tschimmel K., Hoffmann O., Cho S., et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J. Neuroimmunol. 2007, 190:28-33.
39. Lenert P., Stunz L., Yi A.K., Krieg A.M., Ashman R.F. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev. 2001, 11:247-256.
40. Ma K., Mount H.T., McLaurin J. Region-specific distribution of beta-amyloid peptide and cytokine expression in TgCRND8 mice. Neurosci. Lett. 2011, 492:5-10.
41. Marsh B.J., Stenzel-Poore M.P. Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Curr. Opin. Pharmacol. 2008, 8:8-13.
42. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 2006, 6:823-835.
43. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 2009, 10:23-36.
44. Nadeau S., Filali M., Zhang J., Kerr B.J., Rivest S., Soulet D., et al. Functional recovery after peripheral nerve injury is dependent on the pro-inflammatory cytokines IL-1beta and TNF: implications for neuropathic pain. J. Neurosci. 2011, 31:12533-12542.
45. Nicotra L., Loram L.C., Watkins L.R., Hutchinson M.R. Toll-like receptors in chronic pain. Exp. Neurol. 2012, 234:316-329.
46. Obata K., Katsura H., Miyoshi K., Kondo T., Yamanaka H., Kobayashi K., et al. Toll-like receptor 3 contributes to spinal glial activation and tactile allodynia after nerve injury. J. Neurochem. 2008, 105:2249-2259.
47. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004, 173:3916-3924.
48. Peng X.M., Zhou Z.G., Glorioso J.C., Fink D.J., Mata M. Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann. Neurol. 2006, 59:843-851.
49. Peter M., Bode K., Lipford G.B., Eberle F., Heeg K., Dalpke A.H. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology 2008, 123:118-128.
50. Popovich P.G., Horner P.J., Mullin B.B., Stokes B.T. A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury. Exp. Neurol. 1996, 142:258-275.
51. Qi J., Buzas K., Fan H., Cohen J.I., Wang K., Mont E., et al. Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. J. Immunol. 2011, 186:6417-6426.
52. Rabchevsky A.G., Streit W.J. Grafting of cultured microglial cells into the lesioned spinal cord of adult rats enhances neurite outgrowth. J. Neurosci. Res. 1997, 47:34-48.
53. Rossignol S., Schwab M., Schwartz M., Fehlings M.G. Spinal cord injury: time to move?. J. Neurosci. 2007, 27:11782-11792.
54. Schnell L., Fearn S., Klassen H., Schwab M.E., Perry V.H. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur. J. Neurosci. 1999, 11:3648-3658.
55. Schonberg D.L., Popovich P.G., McTigue D.M. Oligodendrocyte generation is differentially influenced by toll-like receptor (TLR) 2 and TLR4-mediated intraspinal macrophage activation. J. Neuropathol. Exp. Neurol. 2007, 66:1124-1135.
56. Stellwagen D., Malenka R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 2006, 440:1054-1059.
57. Stirling D.P., Yong V.W. Dynamics of the inflammatory response after murine spinal cord injury revealed by flow cytometry. J. Neurosci. Res. 2008, 86:1944-1958.
58. Streit W.J., Semple-Rowland S.L., Hurley S.D., Miller R.C., Popovich P.G., Stokes B.T. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp. Neurol. 1998, 152:74-87.
59. Stunz L.L., Lenert P., Peckham D., Yi A.K., Haxhinasto S., Chang M., et al. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur. J. Immunol. 2002, 32:1212-1222.
60. Takeshita S., Takeshita F., Haddad D.E., Janabi N., Klinman D.M. Activation of microglia and astrocytes by CpG oligodeoxynucleotides. Neuroreport 2001, 12:3029-3032.
61. Tang S.C., Lathia J.D., Selvaraj P.K., Jo D.G., Mughal M.R., Cheng A., et al. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 2008, 213:114-121.
62. Tanga F.Y., Nutile-McMenemy N., DeLeo J.A. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5856-5861.
63. Tator C.H., Fehlings M.G. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J. Neurosurg. 1991, 75:15-26.
64. Thompson M.R., Kaminski J.J., Kurt-Jones E.A., Fitzgerald K.A. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011, 3:920-940.
65. Uno H., Matsuyama T., Akita H., Nishimura H., Sugita M. Induction of tumor necrosis factor-alpha in the mouse hippocampus following transient forebrain ischemia. J. Cereb. Blood Flow Metab. 1997, 17:491-499.
66. West A.P., Shadel G.S., Ghosh S. Mitochondria in innate immune responses. Nat. Rev. Immunol. 2011, 11:389-402.
67. Wu F.X., Bian J.J., Miao X.R., Huang S.D., Xu X.W., Gong D.J., et al. Intrathecal siRNA against Toll-like receptor 4 reduces nociception in a rat model of neuropathic pain. Int. J. Med. Sci. 2010, 7:251-259.
68. Yamada H., Gursel I., Takeshita F., Conover J., Ishii K.J., Gursel M., et al. Effect of suppressive DNA on CpG-induced immune activation. J. Immunol. 2002, 169:5590-5594.
69. Yoles E., Hauben E., Palgi O., Agranov E., Gothilf A., Cohen A., et al. Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 2001, 21:3740-3748.
70. Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107.
71. Zhang Y., Lee A.S., Shameli A., Geng X., Finegood D., Santamaria P., et al. TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. J. Immunol. 2010, 184:5645-5653.
72. Zhang L., Berta T., Xu Z.Z., Liu T., Park J.Y., Ji R.R. TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain 2011, 152:419-427.